• Topotecan in Ovarian Cancer: Systematic Evidence and Researc

  2026-07-23

  This Cochrane review rigorously evaluates Topotecan’s efficacy and safety in ovarian cancer treatment, focusing on survival, progression, and toxicity compared to standard regimens. The findings inform both clinical protocol development and preclinical research design, with practical implications for cancer modeling.

• Comparative Pathogenicity of Wild-Type vs E3-Deleted CAdV-2

  2026-07-23

  This study investigates the biological significance of E3 gene deletions in canine adenovirus type 2 (CAdV-2), revealing that a naturally occurring E3-mutated strain retains virulence comparable to wild-type isolates. These findings clarify the functional redundancy of the E3 region and inform future vaccine development and surveillance strategies for canine infectious respiratory disease.

• N-MYC/eIF4G1 Axis Drives Survival in inv(16) Acute Myeloid L

  2026-07-22

  This study uncovers the mechanistic role of N-MYC and its downstream effector eIF4G1 in promoting survival of inv(16) acute myeloid leukemia (AML) cells. The findings reveal a previously unrecognized MYCN enhancer and establish the therapeutic relevance of targeting the N-MYC/eIF4G1 pathway, offering new directions for leukemia research and intervention.

• GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Inhibi

  2026-07-22

  This study demonstrates that upregulation of GLT-1 in astrocytes attenuates neuronal apoptosis and cognitive dysfunction after traumatic brain injury (TBI) by inhibiting the CB1-CREB signaling pathway. The findings provide mechanistic insight into the interplay between glutamate transport, cannabinoid signaling, and secondary injury progression, highlighting new directions for neuroprotection in TBI models.

• Palmitic acid (Hexadecanoic Acid): Technical Workflow Guidan

  2026-07-21

  Palmitic acid (hexadecanoic acid, SKU N2456) provides a high-purity, well-characterized saturated long-chain fatty acid essential for reproducible research in lipid metabolism, metabolic disorder models, and protein palmitoylation regulation. It is not suitable for protocols requiring aqueous solubility or long-term solution storage. Researchers must follow precise reconstitution and immediate-use protocols to ensure consistent results.

• Rosiglitazone (Brl-49653): Advanced Mechanistic Insights for

  2026-07-21

  Delve into the latest scientific advances around Rosiglitazone, a potent PPARγ agonist, and discover its innovative applications in metabolic disease modeling and rare lipodystrophy. This article uniquely integrates mechanistic depth and practical assay guidance for advanced type II diabetes research.

• Mechanistic Insights into Gepotidacin and S. aureus Gyrase I

  2026-07-20

  The reference study dissects the distinct mechanism of action of gepotidacin, a novel bacterial topoisomerase inhibitor, against Staphylococcus aureus DNA gyrase. By contrasting gepotidacin’s effects with those of fluoroquinolone antibiotics, the findings clarify structural and functional principles underlying antibiotic resistance and DNA cleavage specificity—informing both antibacterial development and experimental design in antibiotic toxicity research.

• Phosphatase Inhibitor Cocktail 3 (100X in DMSO): Technical G

  2026-07-20

  Phosphatase Inhibitor Cocktail 3 (100X in DMSO) is designed to prevent loss of protein phosphorylation during sample preparation by inhibiting a broad spectrum of serine/threonine and alkaline phosphatases. It is optimized for use in workflows such as Western blotting, immunoprecipitation, and kinase assays but should not be used in experiments where phosphatase activity is required for the assay outcome.

• Transmission Dynamics of Carbapenemase Genes in CREC in Guan

  2026-07-19

  This study provides a multi-hospital analysis of the genetic mechanisms and epidemiology of carbapenem resistance in Enterobacter cloacae during the COVID-19 pandemic. The findings reveal a predominance of plasmid-borne blaNDM-1 and the high transferability of carbapenemase-encoding genes, highlighting urgent challenges for infection control and research.

• 10058-F4 C-Myc-Max Dimerization Inhibitor: Advanced Workflow

  2026-07-18

  10058-F4 delivers targeted c-Myc-Max dimerization inhibition for reproducible apoptosis and oncogenic transcription studies. Its robust solubility profile and protocol versatility make it a leading choice for acute myeloid leukemia and prostate cancer research. Explore practical workflows, key troubleshooting tips, and cutting-edge insights linking c-Myc transcriptional control to telomerase regulation.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): Precision in Proteasome Inhib

  2026-07-17

  MG-262 (Z-Leu-Leu-Leu-B(OH)2) offers unmatched selectivity and reversibility for proteasome inhibition, uniquely enabling dynamic studies in apoptosis, osteoclast differentiation, and muscle proteostasis. APExBIO delivers this tool with robust quality, supporting advanced workflows for dissecting ubiquitin–proteasome and autophagy pathways.

• MDV3100 (Enzalutamide): Rethinking Senescence and Resistance

  2026-07-17

  Explore how MDV3100 (Enzalutamide) is reshaping translational prostate cancer research by enabling nuanced dissection of androgen receptor signaling, therapy-induced senescence, and resistance mechanisms. This thought-leadership piece synthesizes mechanistic insights, strategic guidance, and the latest evidence—including pivotal findings on senescence phenotypes and combinatorial targeting—to empower next-generation research beyond standard workflows. Contextualized within the competitive landscape and informed by landmark studies, we outline best practices, protocol parameters, and a forward-looking outlook for AR pathway modulation.

• MAZ-BCKDK Axis Drives Glucose Metabolic Rewiring in TNBC

  2026-07-16

  This study uncovers how MAZ-induced upregulation of BCKDK reprograms glucose metabolism in triple-negative breast cancer (TNBC) by stabilizing G6PD, thus fueling tumor growth. The findings highlight a novel metabolic regulatory pathway with therapeutic potential for targeting aggressive breast cancers.

• X-press Tag Peptide: Precision Tools for Quantitative Protei

  2026-07-16

  Explore how X-press Tag Peptide, an advanced N-terminal leader peptide, sets new benchmarks for quantitative protein purification and detection. This article delivers unique, protocol-driven insights, deep molecular rationale, and practical assay guidance beyond existing resources.

• Prednisone in Translational Research: Mechanisms and Strateg

  2026-07-15

  This thought-leadership article dissects the mechanistic and strategic deployment of Prednisone, a synthetic corticosteroid, for translational immunology and neurodegeneration research. Moving beyond standard product pages, we integrate actionable experimental guidance, cross-reference advanced metabolomic modeling from botanical research, and provide a forward-looking perspective for protocol reproducibility and clinical relevance.

15876 records 1/1059 page Next 12345 下5页 Last page